Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain
Kelly F. Contino, Jenna Ollodart, Yang Yu, Sun H. Park, Shunsuke Tsuzuki, Kara Rollins, Tyler M. Heethouse, Joshua Chu, Laiton R. Steele, Takahiro Kimura, Jingyun Lee, Cristina M. Furdui, Lance D. Miller, Fang-Chi Hsu, Yusuke Shiozawa
Kelly F. Contino, Jenna Ollodart, Yang Yu, Sun H. Park, Shunsuke Tsuzuki, Kara Rollins, Tyler M. Heethouse, Joshua Chu, Laiton R. Steele, Takahiro Kimura, Jingyun Lee, Cristina M. Furdui, Lance D. Miller, Fang-Chi Hsu, Yusuke Shiozawa
View: Text | PDF
Research Article Neuroscience Oncology

The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain

  • Text
  • PDF
Abstract

Cancer-induced bone pain (CIBP) is among the most common and debilitating symptoms in patients with bone metastasis. Current treatments are somewhat effective but have severe side effects. For the future development of safer CIBP treatments, in this study, we sought to investigate the mechanisms whereby the nerve-cancer interaction controls CIBP. We found that c-Kit, a receptor tyrosine kinase, was activated in the dorsal root ganglia (DRG) sensory neurons of mice with CIBP and that c-Kit’s sole ligand, stem cell factor (SCF), was enhanced in the bone marrow with bone metastasis. When DRGs were treated with SCF or conditioned medium from high SCF-expressing cancer cells, in vitro nerve sprouting was enhanced, and this effect was abolished with c-Kit inhibitors. Mice inoculated intrafemorally with cancer cells that had varying levels of SCF expression developed CIBP and enhanced peripheral nerve sprouting in an SCF-dependent manner. Downstream proteomic analysis revealed that SCF upregulated and activated fibroblast growth factor 1 (FGF1) in DRGs. When FGF1 was knocked down in DRGs, SCF-mediated nerve sprouting was prevented. Taken together, our studies demonstrate the importance of the SCF/c-Kit axis in CIBP and nerve sprouting and identify the SCF/c-Kit/FGF1 pathway as a potential therapeutic target for CIBP.

Authors

Kelly F. Contino, Jenna Ollodart, Yang Yu, Sun H. Park, Shunsuke Tsuzuki, Kara Rollins, Tyler M. Heethouse, Joshua Chu, Laiton R. Steele, Takahiro Kimura, Jingyun Lee, Cristina M. Furdui, Lance D. Miller, Fang-Chi Hsu, Yusuke Shiozawa

×

Figure 3

SCF is enriched in bone metastatic cancer cells in the bone marrow.

Options: View larger image (or click on image) Download as PowerPoint
SCF is enriched in bone metastatic cancer cells in the bone marrow.
Repr...
Representative IF images of colocalization between cytokeratin-8 (CY8) and SCF and IHC of SCF in (A) bone marrow autopsy samples from patients with prostate cancer who died from other causes (patients without bone mets, n = 4) or bone metastases (patients with bone mets, n = 5); (B) bone marrow of immunodeficient mice inoculated intrafemorally with HBSS (sham mice) and DU145 (DU145-bearing mice) at 54 days posttumor inoculation; and (C) bone marrow of immunocompetent mice inoculated intrafemorally with HBSS (sham mice) and RM-1 (RM-1–bearing mice) at 21 days posttumor inoculation. DAPI was used for nuclear staining. Original magnification, ×20; scale bar: 50 μm for IHC images (first 4 rows and last row). Original magnification, ×60; scale bar: 20 μm for IF images (fifth row). (D) Quantification of SCF positive cells out of total bone marrow cells of (A–C). Mean ± SEM. Student’s t test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). (E) Percentage of SCF expressing CY8 positive cancer cells (SCF+CY8+/CY8+) and CY8 expressing SCF positive cells (SCF+CY8+/SCF+) of (A–C). Mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts